Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
Recruiting · NCT06245629 · Registry updated 2024-11-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell myeloma, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Not stated | 2024-11-29 | NCT06245629 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Dalarna County Council, Sweden | 21 |
| Uppsala County Council, Sweden | 17 |
| Uppsala University | 156 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Akademiska Sjukhuset | Uppsala | Sweden | 20 |